From: Quantitative assessment of radiotherapy-induced myocardial damage using MRI: a systematic review
Study | Patients | Cancer type | Increase | Constant | Dose dependent |
---|---|---|---|---|---|
Van Der Velde et al.,[50] | 80 | HL& NHL | - | No differences with healthy control at 20 years post-RT (28±3% vs 29±3%, p=0.24) | - |
Bergom et al., [48] | 20 | Breast | - | Mean global ECV of 27% (range: 23-34%) at 8.3 years post-RT | - |
Takagi et al., [57] | 24 | Esophagus | In basal septum (high radiated area, 43±4 Gy) in 0.5 year follow up (26±3% vs 32±3%, P<0.01) | - | - |
Tahir et al., [55] | 66 | Breast | - | In epirubicin-chemotherapy-based followed by RT group: (Baseline: 28±2% and 13±2 months: 29±2%, p=0.52) | - |
- | In left-seded RT only group: (baseline: 30±3% and 13±2 months: 30±3%) | - | |||
de Groot et al., [63] | 40 | Esophagus | (28.4±1.0% vs 24.0±0.9%; P<0.001) | - | Linear relation between mean dose per segment and ECV increase (a 0.136%-point increase of ECV for each Gy (P<0.001) at 67.6 months |
Canada et al., [65] | 30 | Chest malignancies | Â | no associations with dose: median 28% [26,27,28,29,30,31] at 2 years post-RT | - |
Mukai-Yatagai et al., [64] | 1 | Esophagus | Increase of ECV (45%) at 8 years | - | - |
Vallabhaneni et al., [54] | 11 | Lung, breast, lymphoma | - | No significant % ECV changes in patients with higher radiation (-11.5±20.8%) or patients with minimal radiation (-8.1±2.9%) at 6-months following RT | - |